title: Outcome of primary glomerular disease in pediatric renal transplantation: a single-center experience.
abstract: BACKGROUND
  The recurrence of primary disease in transplantation is a well-known problem. We report our single-center experience to assess the frequency of the recurrence of primary glomerulonephritis in children after renal transplantation.
  
  
  METHODS
  Medical reports of 14 children with primary glomerular disease were evaluated. Among the 14 grafts were 10 from living related and four from cadaveric donors. Ten were diagnosed as focal segmental glomerulosclerosis (FSGS), two membranoproliferative glomerulonephritis (MPGN), and two polyarteritis nodosa (PAN). The original diagnosis was biopsy-proven in every case. All patients were treated with calcineurin-based immunosuppressive therapy.
  
  
  RESULTS
  The mean age was 15.5 +/- 5.4 years. The median transplantation duration was 47 months; however, one of the FSGS patient had hyperacute rejection. Five years later she received a second graft with a serum creatinine of 0.7 mg/dL at 7 years after transplantation. Posttransplant recurrence of FSGS was confirmed in two patients (20%), who were treated with plasmapheresis with no improvement of proteinuria, two FSGS patients had thromboses after transplantation. One had a cardiac thrombosis with heterozygote MTHFR mutation and one, a renal artery thrombosis and loss of graft with prothrombin 20210A mutation. They all have functioning grafts except these two. We did not observe recurrence of PAN or MPGN in patients.
  
  
  CONCLUSIONS
  Although the number of patients is quite small, our recurrence rate was compatible with the previous reports. Additionally, we strongly recommend evaluation of all risk factors for thrombosis and give appropriate anticoagulation.
authors.affiliation: Department of Pediatrics Nephrology Unit, Hacettepe University School of Medicine, Ankara, Turkey.
authors.forename: Y
authors.initials: Y
authors.lastname: Bilginer
authors.forename: R
authors.initials: R
authors.lastname: Topaloglu
authors.forename: F T
authors.initials: FT
authors.lastname: Aki
authors.forename: E
authors.initials: E
authors.lastname: Demirkaya
authors.forename: F
authors.initials: F
authors.lastname: Ozaltin
authors.forename: N
authors.initials: N
authors.lastname: Besbas
authors.forename: S
authors.initials: S
authors.lastname: Ozen
authors.forename: A
authors.initials: A
authors.lastname: Bakkaloglu
authors.forename: I
authors.initials: I
authors.lastname: Erkan
authors.forename: M
authors.initials: M
authors.lastname: Bakkaloglu
mesh_terms: D000293:Adolescent; D000328:Adult; D002102:Cadaver; D002648:Child; D015432:Glomerulonephritis, Membranoproliferative / Q000601:surgery; D005923:Glomerulosclerosis, Focal Segmental / Q000601:surgery; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000601:surgery; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology / Q000706:statistics & numerical data*; D019520:Living Donors; D010488:Polyarteritis Nodosa / Q000601:surgery; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents